Israel Englander Immatics N.V. Call Options Transaction History

Millennium Management LLC

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$10.93 - $12.92 $189,089 - $223,516	-17,300 Reduced 34.6%	32,700 $373,000
Q2 2024 Aug 14, 2024	BUY	$9.78 - $13.49 $488,999 - $674,500	50,000 New	50,000 $581,000
Q4 2023 Feb 14, 2024	BUY	$7.36 - $10.89 $325,312 - $481,338	44,200 New	44,200 $465,000

101

75.8M

238K

727K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $579M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.